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Purpose: The importance of oxidative stress in both the formation and the course of glaucoma has been known. Among
the antioxidants, vitamin E possesses the specific effects and regulatory mechanisms of a neurohormone. The serum
oxidant/antioxidant profile is reportedly altered in ocular pathologies. In this study, we analyzed the effect of the clinical
parameters of glaucoma and biochemical data on antioxidants and serum oxidative stress markers as oxidation degradation
products.
Methods: In this multicenter case control study, control and patient groups consisted of 31 healthy individuals and 160
glaucoma patients with no known additional abnormalities, respectively. We analyzed the oxidation degradation products
malonyl dialdehyde (MDA), advanced oxidation protein products (AOPP), antioxidants, vitamins E and A, Serine (Ser),
superoxide dismutase (SOD), glutathione peroxidase (Gpx), transferrine (TF), and total antioxidant capacity (TADA). All
of these parameters and their relationships with serum cholesterol, glucose, protein, albumin, triglyceride levels, age,
gender,  visual  acuities,  intraocular  pressure  (IOP),  c/d  ratio,  gonioscopic  findings,  medications,  presence  of
pseudoexfoliation (px), central visual field and Optical Coherence Tomography (OCT) data, pachymetry, and Laplace
values, were evaluated individually. Statistical comparisons were performed among them, and with the control group as
well.
Results: TADA, AOPP, SOD, and Gpx were found to be decreased, and MDA, Ser, TF, vitamins A and E increased in
the patient group. All data, excluding AOPP, varied significantly. Vitamin E was the most consistent parameter.
Conclusions: In this study, the association between glaucoma and lipid oxidation was shown on a systematic basis, and
the significance of vitamin E as a neuroprotective agent has been revealed once more.
Although  glaucoma  (recognized  as  the  most  frequent
cause  of  irreversible  blindness),  is  characterized  by
progressive retinal ganglion cell loss, it was regarded for years
as “a disease associated with an increase in the intraocular
pressure (IOP)” [1]. Even if increased IOP has been excluded
from  the  definition  of  glaucoma,  considered  a  major  risk
factor, and glaucoma has been defined as an optic neuropathy,
current clinical applications strongly aim to decrease IOP.
Though we have effective medical and surgical therapies at
hand, progressive visual loss is still a prevalent symptom in
glaucoma cases [2]. In light of current knowledge, a valid
hypothesis is that ganglion cell death (apoptosis) observed in
glaucoma is caused by a special type ischemia. Indeed, the
clinical manifestations of glaucoma are different from other
ischemic pathologies. Beyond animal experiments, ischemia
and glaucoma can be induced by an increase in IOP, and quite
different  abnormalities  have  been  observed  using  various
methods, such as carotid occlusion [3]. In another study, the
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role of oxidative damage in the etiopathogenesis of glaucoma
was explained by the production of reactive oxygen species
secondary to a complex trabecular mitochondrial defect [4].
Tissue damage due to oxidation is a chain reaction, which
is mainly initiated by the production of free oxygen radicals.
Though  these  molecules  interact  with  intracellular  signal
conduction  and  regulation  mechanisms,  they  demonstrate
their main effects as destructive changes induced by a series
of DNA reactions and macromolecules, such as proteins and
lipids [5]. Oxidation degradation products, which are tissue
and  serum  markers  of  this  destructive  process,  consist  of
malonyl dialdehyde (MDA), advanced lipid oxidation end-
products (ALEs) for lipids, and advanced oxidation protein
products (AOPPs) for proteins [6]. Vitamins E, C, and A,
molecules  like  homocysteine,  and  transferrine  (TF)  bind
oxygen ions and transform into steady-state compounds with
their resultant antioxidant effects. Serine (Ser) is an amino
acid used in the effect pathway of vitamin E. These buffer
compounds  that  are  formed  offer  their  ions  to  the
downregulating (velocity-limiting) systems, which consist of
superoxide  dismutase  (SOD)  and  glutathione  peroxidase
(Gpx), to curtail chain reactions [7]. The nervous system,
which also includes retina ganglion cells, is rich in lipids.
Further, metabolic rate, oxygen degradation, and synthesis of
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1260ATP  are  increased  in  these  cells,  while  the  cellular
regeneration  rate  is  restricted.  Dopamine  oxidation  and
chemical  factors  (e.g.,  glutamate)  are  also  important.
Secondary to all of these factors, nerve cells are quite sensitive
to oxidative damage [5].
The  use  of  antioxidants  for  the  prevention  of
glaucomatous decay is also addressed. Higher lipid contents
of nerve cells has enhanced the importance of lipid-soluble
vitamin E, especially α-tocopherol, which has hormone-like
regulatory mechanisms with its unique transporter proteins
and receptors, exerting neuromodulatory effects on the eye
and  other  tissues.  Neuroprotective  effects  of  vitamin  E
compounds  in  retinal  diseases  and  glaucoma  have  been
clincally demonstrated [8]. Ginkgo biloba extracts are also
neuroprotective antioxidants [9]. Both vitamin E compounds
[10],  and  ginkgo  biloba  extracts  [11]  also  manifest
vasoregulatory activities in the retina, which are significant
for the prevention of ischemia.
As  a  form  of  optic  neuropathy,  glaucoma  has  also
demonstrated  central  nervous  system  pathologies  in
experimental [12], and clinical [13,14] studies. In addition to
the pathogenesis of all types of glaucoma, oxidative damage
plays a key role [5,15]. In our study, we investigated the
effects of the clinical parameters of glaucoma, and relevant
biochemical parameters on various oxidative stress indicators,
such  as  increments  in  various  antioxidants  and  oxidative
degradation products in serum samples.
METHODS
Control  and  patient  groups  consisted  of  31  and  160
individuals, respectively (Table 1). With routine examination,
there  were  no  findings  implying  ophthalmic  pathologies,
including glaucoma or ocular hypertension, in the control
group. Patients with no known ocular or systemic concomitant
disorders,  previous  glaucoma  surgeries,  and  antioxidant
usage, who received follow-up in our glaucoma polyclinics,
were selected for the patient group. For both groups, oxidation
degradation products (MDA and AOPP), antioxidants (e.g.,
vitamins  E  and  A),  Gpx,  and  total  antioxidant  capacity
(TADA)  were  studied,  in  addition  to  routine  blood
biochemical tests for cholesterol, glucose, protein, albumin,
and  triglyceride.  All  of  these  parameteres  with  their
relationships to blood cholesterol, glucose, protein, albumin
and triglyceride levels, age, gender, visual acuity, intraocular
pressure,  c/d  ratio,  gonioscopic  findings,  drugs  used,  the
presence of pseudoexfoliation (px), central field of vision,
Mean  deviation  (MD)-  Pattern  Standart  Deviation  (PSD),
pachymetry,  and  eye  wall  stress  (Laplace’s  value),  were
evaluated individually. The patients were examined on the day
of blood sample collection. The patients with visual acuities
less than 5/10 in one eye were considered to have lower visual
acuity.  IOPs  and  c/d  ratios  were  taken  with  the  Pascal
Dynamic Contour tonometry (Nidek Inc., Fremont, CA) and
RTVue-100 fourier domain Optical Coherens Tomography
(OCT) (Nidek Inc.), respectively. Patients with IOPs higher
than 21 mmHg in one or both eyes were evaluated as mono-
or bilateral higher IOP groups, respectively, while those with
c/d ratios more than 0.5 in one or both eyes were assessed as
mono-or  bilaterally  increased  IOP  groups,  respectively.
Visual fields were taken with the Humphrey Field Analyzer
Model  740i  (Carl  Zeiss  Inc.  Dublin,  CA).  Patients  with
glaucomateus visual field defects in one or both eyes were
evaluated  as  mono-or  bilateral  visual  field  defect  groups,
respectively.
Corneal thickness <555 or >558 constituted groups with
thinner or thicker corneas, respectively [16]. In gonioscopic
examination, patients with grade ≤2 consisted of narrow-angle
glaucoma patients, and the patients were divided into those
using single (prostaglandin analogs, beta blockers), 2 and 3
drops,  or  patients  without  medications.  Prostaglandin
analoges  and  beta  blockers  were  included  in  all  of  the
combinations, and fixed combinations were considered as
single drops. Corneal thickness of the patients were measured
with the Pocket II pachymeter device (Quantel medical inc.
Bozeman, MO). Axial diameters of corneas were measured
with the AB5500+ (Sonomed Inc., L Success, NY) A scan
mode, and together with the results of the pachymetre, the
Laplace formula was applied [17]. Patients with IOPs higher
or lower than normal eye wall stress values constituted higher
and lower Laplace groups.
These  results  were  compared  statistically  among  one
another, as well as with those of the control group. When
sample sizes in all groups were appropriate for parametric
tests, the Student t-test and Mann–Whitney U tests were used.
Test results were evaluated as moderately (p<0.01), highly
(p<0.005), or extremely (p<0.001) significant.
TABLE 1. COMPARISON OF CONTROL AND PATIENT GROUPS.
Parameters Control group Patient group
Mean age 44.87±10.78 50.96±14.19
Gender (F/M) 15/16 106/54
Cholesterol 173±46.67 201.23±43.25
Glucose 86±5.66 119.76±58.54
Triglyceride 118±38.18 170.46±86.84
Protein 0.78±7.95 8.05±0.6
Albumin 4.67±0.21 4.71±0.25
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1261Biochemical analyses: Routine biochemical analyses for
serum  glucose,  cholesterol,  triglyceride,  total  protein,  and
albumin were performed using the Roche autoanalyser DP
(Roche Diagnostics Ltd. W Sussex, UK) modular calorimetric
analytical method, while for other measurements were done
manually.
Measurement of advanced oxidation protein products
(AOPP)—AOPP  levels  were  studied  in  the  AU  2700
autoanalyser  (Olympus  Diagnostics  Inc.  Melville,  NY).
Blood samples were drawn from cubital veins in tubes with
EDTA (EDTA), and centrifuged at 1660× g and 4 °C for 10
min. The blood samples were divided in aliquots and kept in
Eppendorf tubes at −20 °C. All samples were analyzed within
approximately 30 days. After preparation of chloramine-T
stock solution (10 mmol/l), they were diluted 100 times with
PBS (20 mmol/l, pH:7.4) to obtain a main standard solution
at 100 µmol/l concentration (standard 1). Chloramine-T main
standard solution (standard 1:100 µmol/l) was diluted with
PBS (20 mmol/l, pH 7.4) to get a 5-point calibration curve,
and lso to prepare Chloramine-T standards at 75, 50, 25, and
12.5 µmol/l concentrations. PBS (160 µl) was added to 40 µl
standard  or  plasma,  mixed,  and  incubated  for  25  s.  The
absorbance of the mixture was read at 340 nm, then 20 µl of
acetic acid was added and incubated for 25 s. Finally, 10 µl
KI  solution  was  added  and  reincubated  for  25  s,  and  its
absorbance was read again. All steps were completed at 37 °C
in a single cuvette. Time intervals were arranged at every step
as 25 s or longer based on the program characteristics of the
analyzer.  A  calibration  curve  was  formulated  using
absorbance (A) values corresponding to the concentrations of
5 standard solutions. AOPP concentration was reported as
µmol  Chloramine-T/l,  corresponding  to  the  absorbance
measured.
Measurement of malonyl dialdehyde (MDA)—Blood
samples drawn from the cubital vein were placed in blood
tubes containing EDTA as an anticoagulant. Plasma samples
were separated rapidly, and cryopreserved at −70 °C Samples
were not thawed and refrozen, and they were also not exposed
to light to avoid photooxidation. A 140 µl standard, sample,
and  reagent  blank,  were  placed  individually  into
microcentrifuge tubes. “Reagent“ (455 µl) was then added
into each tube and vortexed. HCl (105 µl; 12 N [37%]) was
added into each tube as well. The tubes were stirred throughly,
tapped close, and incubated at 95 °C for 60 min in a milleu of
acidity provided by HCl. Then, 1 molecule of MDA and 2
molecules of reagent (N-methyl-2-phenylenilindol) reacted
with each other to yield a stable chromophor product (colored
product),  which  might  provide  a  maximal  absorbance
spectrum at a 586 nm wavelength. Centrifugation at 13,000×
g for 15 min yielded a clear supernatant sample. This sample
(150 µl) was placed in each well. Their fluorescent activities
were measured on a microplate reader (SynergyTM 2 Multi-
Mode; BioTek Instruments, Inc., Vinooski, VT) at 500 nm
(±30) excitation, and 586 nm (±30) emission. Using a y=ax+b
formula  derived  from  the  absorbance-concentration
correlation of standards used for the construction of the MDA
standard curve, and absorbance data obtained, the analyzer
automatically calculated MDA concentrations, and the results
were expressed as “µmol/l.”
Measurement of TADA—Blood samples drawn from
the cubital vein were taken into gelatinized tubes with no
anticoagulant, centrifuged at 3,000× g, and 4 °C for 12 min,
and  their  plasma  components  were  separated  into  two
aliquots.  Dilution  buffer,  copper,  and  stop  solutions  were
preserved  at  2–8  °C,  and  working  samples  were  kept  as
“aliquots” at −70 °C. Before measurements, dilution buffer,
copper, and stop solutions were kept under room temperature
for 30 min. To obtain a standard solution, 1.5 ml deionized
water, and uric acid standard were added, and the prepared
solution was vortexed until it dissolved thoroughly to obtain
a “uric acid standard” with a final concentration of 2 nM.
From this stock standard solution, 5 working standards
were obtained using serial dilutions. A dilution buffer was
used  in  1:4  dilutions  of  standard  and  sample  solutions.
Standard and sample solutions were diluted with the dilution
buffer. Diluted standard, samples, reagent blank, and 200 µl
buffer  were  pipetted  into  every  well.  The  reagent  blank
contained buffer solution for dilution and the standard/sample
solution.  At  490  nm  wavelength  using  a  Roche  COBAS
MIRA Plus Chemistry Analyzer (Roche Diagnostics Ltd. W
Sussex, UK), the absorbances of reagent blank, standard, and
samples were read. Copper solution (50 µl) was added in each
well,  excluding  wells  containing  reagent  blank,  incubated
under  room  temperature  for  3  min,  and  the  reaction  was
finalized after adding 50 µl stop solution in each well. A
second  reading  was  done  for  absorbance  at  490  nm
wavelength. Under the combined effects of the sample of
antioxidants in the standard solution, Cu+ (ferric form) in the
copper solution is reduced into Cu2+ (ferro form), and a color
reaction yielding maximal absorbance at 490 nm wavelength
is  formed.  Using  spectrophotometry,  total  antioxidant
capacity (TAC) was automatically estimated based on the
equation y=ax+b, derived from uric acid standard curve, and
the results were recorded.
Determination  of  superoxide  dismutase  (SOD)
activity—Blood samples were drawn from the cubital vein,
placed into tubes containing EDTA as an anticoagulant, and
centrifuged at 1,000× g and 4 °C for 10 min. Supernatant
plasma was drawn using a pipette, and then discarded. The
samples were mixed 4 times with ice water to disintegrate
RBCs. A 250 µl sample and 400 µl of a ethanol/chloroform
(62.5/37.5)  solution  were  mixed  to  measure  Cu-Zn  SOD
activity. Thus, inactivation of mitochondrial Mn-SOD and Fe-
SOD by ethanol/chloroform mixture was achieved. Then, this
mixture was centrifuged at 3,000× g and 4 °C for a minimum
of 30 s. The samples were frozen at −70 °C, and analyzed
within 1 month. The Roche COBAS MIRA Plus Chemistry
Analyzer (Roche Diagnostics Ltd. W Sussex, UK) was used
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1262for  manual  measurement  procedure.  The  results  were
evaluated in comparison with hemoglobin concentrations.
The  determination  of  erythrocyte  Gpx  activity  was
achieved using a Cellular Glutathione Peroxidase kit (Cayman
Chemical Ann Arbor, MI), modified for the Roche COBAS
MIRA  Plus  analyzer  (Roche  Diagnostica).  Gpx
concentrations were calculated based on the Equation 1 mU/
ml=1  nmol  NADPH/ml/min=(A3,  40min)/0.00622.  The
results  were  evaluated  in  comparison  with  hemoglobin
concentrations.
Transferrine  (TF)  analyses  were  performed  using  a
Beckman kit.
Levels of vitamins E and A were measured using High
Perfusion  Lipid  Chromatography  (HPLC).  The  patient’s
serum (200 µl) was placed into a tube and reacted with 200 µl
(1 g/l) ethanol ascorbate to deproteinize. Asetonitrile (24 µl)
was added to the mixture, and then vortexed for 1 min. Next,
500 µl of HPLC grade hexane was added to this solution,
vortexed for 2 min, centrifuged at 770× g for 1 min,and a
supernatant hexane phase was collected. This procedure was
repeated  3  times.  Vitamins  A  and  E  were  derived  from
approximately  1,500  µl  of  hexane  solution  in  these
procedures. A completely clear 1,250 µl solution was drawn
from  the  tube,  removing  a  small  amount  of  precipitated
sediment that as present in the bottom of the tube. The hexane
was completely evaporated under liquid nitrogen in a water
bath at 36 °C. The tubes were closed watertight with paraffin,
and prepared for the test. To perform the HPLC procedure,
10 µl (1 g/l) ethanol ascorbate was added to the sediment at
the bottom of the tube, and then vortexed. Then, 150 µl of
mobile phase (methanol:water; 95.5) was added, vortexed for
1 min, and degassed by sonication for 1 min. The mixture was
sieved through a 45 nm filter. A 50 µl sample was removed
from this filtered solution, injected into the HPLC Chrome-
system column at a flow rate of 1.5 ml/min, and using the
Knauer UV detector (Knauer Inc. Berlin, Germany), vitamins
E and A were read at 295 nm and 320 nm, respectively. Peaks
of vitamins A and E, which were derived individually from
chromatograms obtained from the Spectra-Physics integrator
(Triad  Scientific  Inc.  Lakewood,  NJ),  were  compared  to
calculate concentrations expressed as μg/ml.
RESULTS
In comparison to the control group, TADA, AOPP, SOD, and
Gpx were found to be decreased, while MDA, Ser, TF, and
vitamins A and E increased in the patient group (Figure 1).
Excluding AOPP, all data varied significantly.
For vitamin E and MDA, this increase was found to be
extremely  significant.  In  the  hypertriglyceridemia  group,
MDA, vitamin E, TADA, Gpx, SOD, and TF levels varied
significantly.  In  the  hypo-and  hyperproteinemia  groups,
MDA,  and  TADA  levels  varied  significantly,  and  in  the
hypercholesterolemia  group,  all  data  (excluding  AOPP)
varied  significantly.  Vitamin  E  demonstrated  extremely
significant  increases  among  all  glycemia  groups,  in
hypercholesterolemia, and hypertriglyceridemia, as well as in
hyper-and normoproteinemia groups. In the hyperproteinemia
group,  an  increase  in  Ser  was  found  to  be  extremely
significant. MDA increments were of utmost significance in
the  hypercholesterolemia  group,  while  in  the
Figure 1. Comparison of the oxidative stress results between control and patient groups.
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1264hypertriglyceridemia  group,  they  were  observed  to  be
extremely significant (Table 2 and Table 3). The presence of
px induces decreases in TADA and AOPP, and increases in
MDA and vitamin E levels, while in the wide-angle glaucoma
patients, TADA was lower. In both wide and narrow-angle
glaucoma cases, MDA and vitamin E levels were found to be
higher. In the lower visual acuity group, MDA and vitamin E
increased and SOD decreased, while in the higher IOP group,
TADA was found to be significantly lower. Higher Laplace
and c/d values significantly influenced TADA and vitamin E.
Vitamin  E  demonstrated  extremely  higher  levels  in  both
genders, all ages, IOPs, and age groups, as well as in patients
manifesting bilateral c/d abnormalities. In addition to having
extremely higher decreases in TADA levels in 40- to 60-year-
old patients and normal IOPs, and wide-angle glaucomas, and
extremely higher increases in MDA concentrations in age-
matched cases, normal visual acuities and higher IOPs were
observed  (Table  4  and  Table  5).  Furthermore,  vitamin  E
showed extremely higher levels in all MD and PSD groups,
and thicker cornea groups as well. In addition, vitamins E and
A were found to be extremely higher in groups of patients with
increased  Laplace  values.  Significant  differences  were
observed in MDA, vitamin E, SOD, and TADA levels in
groups with higher MD and PSD values (Table 6 and Table
7).
When compared with the normal control groups, MDA
levels in the group of patients with hyperglycemia, px, and
Gpx levels, in cases with bilaterally higher c/d, ratios were
found  to  be  extremely  higher  and  lower,  respectively.  In
addition, in the group with lower visual acuity, MDA and
vitamin E levels were moderately higher and SOD levels were
moderately lower when compared to the patients with normal
visual  acuities.  Vitamins  E  and  A  were  found  to  be
significantly increased in the group with higher IOP Laplace
scores as well.
DISCUSSION
Glaucoma, being a nonsystemic disease, is the most frequent
etiology of irreversible blindness worldwide is not only an
ocular pathology [13]. However, studies related to its effects
on serum oxidative stress markers are quite limited in the
existing literature. In ocular pathologies, such as Behçet’s
disease [18] and cataract [19], the serum oxidant/antioxidant
profile was reportedly altered. However, in glaucoma, it was
determined that the serum glutathion concentration decreased
[20], and composition of blood fatty acids were altered [21].
In this study, the effects of 5 biochemical and 12 clinical
parameters on serum levels of oxidation degradation products
and 8 antioxidants were examined.
In the main comparison between the patient and control
groups, the observation of significant differences in all data
(excluding  AOPP)  should  be  emphasized.  In  this  study,
TADA,  protein  oxidation  end  product  AOPP,  and  the
enzymes SOD and Gpx, were found to be decreased. On the
other hand, lipid oxidation end product MDA, Ser and TF, and
liposoluble vitamins A and E increased in the patient group.
Glaucoma is an optic neuropathy, and oxidative stress plays
an important role in its etiopathogenesis. Thus, adipose tissue
damage  is  its  predominant  characteristic  [5].  Oxidative
reactions occurring within tissues lead to the formation of
different end-products, according to the molecules they affect.
Among these end-products that can be traced in serum, AAOP
TABLE 3. STATISTICAL SIGNIFICANCE OF SERUM OXIDATIVE STRESS MARKERS BASED ON BIOCHEMICAL PARAMETERS.
Parameters Groups TADA AOPP SOD Gpx MDA Ser TF Vit A Vit E
Cholesterol H         *       **
  I ***   * * *** *   * ***
  N **   *   **   *   **
Glucose                  
  H           **     *
  I *       *   *   ***
  N ***   * * *** *     ***
Triglyceride H         * * *   *
  I         ***       ***
  N *       *   *   ***
Protein I *       *** *** *   ***
  N ***     * ***       ***
  D         *        
Albumin I               * ***
  N         *        
  D ***       ***       ***
TADA: total antioxidant capacity, AOPP: advanced oxidation protein products, SOD: superoxide dismutase, Gpx: glutathione
peroxidase,  MDA: malonyl dialdehyde, Ser: Serine, TF: transferrine, Vit A: vitamin A, Vit: E: vitamin E, H: Very high I:
Increased, D: Decreased, N: Normal, n: number., *:p<0.01 moderately significant,**: p<0.005 very significant, ***: p<0.001
extremely significant.
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1266is formed as a result of protein degradation [22]. Further, the
increments in levels of vitamin E and MDA in the patient
group were found to be extremely significant. Vitamins A and
E  are  lipid  soluble  [23],  and  MDA  is  a  lipid  oxidation
degradation  product  [24].  In  glaucoma  patients,  MDA
increases twofold in the anterior chamber [25], and in cases
with cataract, its serum levels are also enhanced [19]. Since
retina and nervous tissue are rich in lipid, these results are
significant. In addition, in the hypertriglyceridemia group,
TADA, Gpx, and SOD were statistically significantly lower,
and TF, MDA, and vitamin E were statistically significantly
higher. On the other hand, in the hypercholesterolemia group,
significant differences in all parameters, except AOPP, were
observed,  which  demonstrates  the  importance  of  lipid
metabolism in the pathogenesis of glaucoma. This is also
consistent with previous findings [21]. Addtitionally, the most
significant  and  consistent  results  were  observed  for  all
parameters in the levels of vitamin E. However, in intergroup
comparisons between MDA and TADA, as well as with the
control group, the most frequently encountered significant
elevations were noted for oxidative stress indicators.
When compared with the control group, vitamin E was
significantly elevated in all patients except for those with
normal corneal thickness, lower Laplace scores, normal c/d,
px(-),  and  hypoproteinemia.  However,  lipid-soluble
antioxidant vitamin A only exhibited extremely higher levels
in  patients  with  higher  Laplace  scores.  These  results
emphasize vitamin E as an antioxidant and a neurohormone.
It  is  recognized  that  oral  or  parenteral  vitamin  E
accumulates more frequently inside the retina [26]. A study
conducted  on  human  eyes  reported  that  retinal  vitamin  E
levels were higher than those found in choroidal and vitreal
tissues, and were directly proportional to serum vitamin E
levels [27]. In animal trials, oral or parenteral administration
of  100  mg/kg  dl-α-tocopheril  acetate  were  reported  to
similarly induce 3–6 fold increases in plasma levels, while
after oral intake, retinal and vitreal levels were achieved later
[28].  Apart  from  other  antioxidants,  vitamin  E  contains
sensitive  mechanisms  for  the  regulation  of  tissue  surface.
Discovery  of  the  tocopherol  transfer  protein,  specific
membrane  receptors,  and  cytosolic  transfer  proteins,  has
suggested that this molecule might have other functions apart
from its antioxidant effects. Indeed, many in vivo and in vitro
studies  performed  in  normal  and  neoplastic  cells  have
demonstrated that α-tocopherol had specific effects, including
gene regulation [29]. We have specific evidence that this
phenomenon also applies to ocular tissues [30]. Again, it has
been  established  that  some  vitamin  E  derivatives  act  as
neurohormones, and initiate various intracellular conduction
pathways with a lock –and-key model. Cell culture and animal
studies have confirmed that, among these specific effects,
those on PKC were unique for PKC, and closer isomers (e.g.,
TABLE 5. STATISTICAL SIGNIFICANCE OF SERUM OXIDATIVE STRESS MARKERS BASED ON CLINICAL PARAMETERS.
Parameters Groups TADA AOPP SOD Gpx MDA Ser TF Vit A Vit E
Gender Female **       **       ***
  Male **       **     * ***
Age (years) <40 *   ***   *   *   ***
  40–60 ***       ***   *   ***
  >60       * *       ***
Visual acuity N *       *** * *   ***
  D     *   *       *
IOP N ***   *   * *   * ***
  U *       ***       ***
  B     *   *** *     ***
c/d N ***   * *** *** * *    
  U         **   *   **
  B *     *** *       ***
Angle Wide ***     * ***   *   ***
  Narrow         * ***   * ***
Drugs (-)     * * ***   *   ***
  PG *       *     * **
  β-b     *   **       **
  2 drugs                
  3 drugs                
Px (+)   *     ***       **
  (-)       * **       *
TADA: total antioxidant capacity, AOPP: advanced oxidation protein products, SOD: superoxide dismutase, Gpx: glutathione
peroxidase,  MDA: malonyl dialdehyde, Ser: Serine, TF: transferrine, Vit A: vitamin A, Vit: E: vitamin E, U: Unilateral, B:
Bilateral,  D:  Decreased,  N:  Normal,  PG:  Prostaglandin  analogous,  β-b:  β-blocker,  n:  number,  *:p<0.01  moderately
significant,**: p<0.005 very significant, ***: p<0.001 extremely significant.
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1269β-tocopherol),  and  distinct  antioxidants  (e.g.,  probucol),
lacked these effects [31]. Various trials have reported that
retinal vascular dysfunction secondary to hyperglycemia is
corrected by α-tocopherol through the DAG-PKC pathway
[32].
Regarding  glaucoma,  the  PKC  pathway  also  has
significant effects on non-vascular ocular smooth muscles,
including trabecular meshork of the eye [33], PGF2α, and
matrix metalloproteinases [34]. In addition, some publications
have stated that glutamine transporter activity, which plays a
key role in neurodegeneration, is regulated by PKC [35].
Retinal blood flow regulating and neuroprotective effects of
α-tocopherol  in  glaucoma  patients  have  been  clinically
demonstrated [10]. Moreover, α-tocopherol is recognized for
prolonging life span in retinal cell cultures [36]. Taking all of
these  issues  into  consideration,  significant  and  consistent
elevation manifested by vitamin E, which has a special role
among  antioxidants  [8]  in  glaucoma  patients,  is  very
important.
Elevations in Ser in the hyperproteinemia group were
found to be extremely significant. Ser is an aminoacid that
plays an important role in the antioxidant and neuromodulator
effects of vitamin E [37]. Another important point is that PKC,
which interacts with α-tocopherol, is a type of Ser/Treonin
kinase [38].
Another  elevated  liposoluble  vitamin  was  vitamin  A.
Similar to tocopherols, vitamin A derivatives are also known
to  be  neuromodulators  in  the  retina  [39],  to  improve
endothelial function by reducing the concentration of reactive
oxygen species in the vessel wall [40], and possess specific
receptors in the nervous system [41].
In addition, Vitamin E and MDA elevations observed in
the px(+) group (which was more significant than that of px(-)
group,  but  meaningful  relative  to  the  control  group)  are
consistent with the literature. The study performed by Yılmaz
et al., which demonstrated that MDA levels in cataract patients
with px were higher when compared with other forms of
cataract,  has  been  among  trials  indicating  that  an  ocular
pathology could affect serum oxidative stress markers [42].
In this study, clinical findings on the effects of glaucoma
on oxidative stress indicators have been demonstrated to shed
light  on  the  pathogenesis  of  glaucoma.  The  association
between glaucoma and lipid oxidation has been revealed as
well. Another point to be emphasized is that, in addition to
being an antioxidant, vitamin E has unique neurohormone-
like activities and regulatory mechanisms, and its serum levels
increase in conjunction with the severity of clinical findings
of glaucoma. Further studies are needed to conclude that this
molecule is the sole predictor of glaucoma. However, based
on the results of this study, the significance of vitamin E as a
neuroprotective  agent  with  neurohormone-like  activities,
independent to being an antioxidant, has been revealed once
more.
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